Answers are grounded in this paper and cite their sources.
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
No takes yet. Share an insight, caveat, or question.
Young et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: